Geographically, 37% of our sales in the second quarter were in the U.S. compare to 42% last year with 63% of our sales outside the U.S. compared to 58% last year. The reason for the change from last year is clearly due to Laprolan acquisition. Bottom-line, these results indicate that we are executing well in both our U.S. and international businesses.
Rochester Medical's CEO Discusses F2Q11 Results - Earning Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.